Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
J Exp Med. 2014 Dec 15;211(13):2497-505. doi: 10.1084/jem.20140987. Epub 2014 Dec 8.
Adult T cell leukemia/lymphoma (ATLL) is an aggressive malignancy caused by human T cell lymphotropic virus type-I (HTLV-I) without curative treatment at present. To illuminate the pathogenesis of ATLL we performed whole transcriptome sequencing of purified ATLL patient samples and discovered recurrent somatic mutations in CCR4, encoding CC chemokine receptor 4. CCR4 mutations were detected in 14/53 ATLL samples (26%) and consisted exclusively of nonsense or frameshift mutations that truncated the coding region at C329, Q330, or Y331 in the carboxy terminus. Functionally, the CCR4-Q330 nonsense isoform was gain-of-function because it increased cell migration toward the CCR4 ligands CCL17 and CCL22, in part by impairing receptor internalization. This mutant enhanced PI(3) kinase/AKT activation after receptor engagement by CCL22 in ATLL cells and conferred a growth advantage in long-term in vitro cultures. These findings implicate somatic gain-of-function CCR4 mutations in the pathogenesis of ATLL and suggest that inhibition of CCR4 signaling might have therapeutic potential in this refractory malignancy.
成人 T 细胞白血病/淋巴瘤(ATLL)是一种由人类 T 细胞白血病病毒-1(HTLV-I)引起的侵袭性恶性肿瘤,目前尚无治愈方法。为了阐明 ATLL 的发病机制,我们对纯化的 ATLL 患者样本进行了全转录组测序,发现了 CC 趋化因子受体 4(编码 CC 趋化因子受体 4)的频繁体细胞突变。在 53 例 ATLL 样本中的 14 例(26%)中检测到 CCR4 突变,这些突变仅为无义或移码突变,导致羧基末端 C329、Q330 或 Y331 处的编码区截断。功能上,CCR4-Q330 无义异构体具有功能获得性,因为它增加了细胞向 CCR4 配体 CCL17 和 CCL22 的迁移,部分是通过削弱受体内化。这种突变体增强了 ATLL 细胞中 CCL22 结合受体后 PI(3)激酶/AKT 的激活,并在长期体外培养中赋予了生长优势。这些发现提示体细胞功能获得性 CCR4 突变参与了 ATLL 的发病机制,并表明抑制 CCR4 信号可能具有治疗这种难治性恶性肿瘤的潜力。